DSE : CENTRALPHL
Central Pharmaceuticals Ltd. — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 8.3 BDT (At close: Oct 29, 2026) · Market cap 994.35M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 994.35M |
| Enterprise Value | 1.26B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 119.80M |
| Shares Outstanding | 119.80M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 7.67% |
| Owned by Institutions (%) | n/a |
| Float | 110.61M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.55 |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 34.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.06 |
| Quick Ratio | 0.20 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 94.91 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -2.16% |
| Return on Capital Employed (ROCE) | -2.20% |
| Weighted Average Cost of Capital (WACC) | 4.67% |
| Revenue Per Employee | 481,281 |
| Profits Per Employee | -288,979 |
| Employee Count | 75 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.60M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -3.49% |
| 50-Day Moving Average | 9.30 |
| 200-Day Moving Average | 9.27 |
| Relative Strength Index (RSI) | 37.01 |
| Average Volume (20 Days) | 203,878 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 36.10M |
| Gross Profit | -11.43M |
| Operating Income | -23.27M |
| Pretax Income | -23.28M |
| Net Income | -21.67M |
| EBITDA | 2.83M |
| EBIT | -23.27M |
| Loss Per Share | -0.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.24M |
| Total Debt | 268.47M |
| Net Cash | -267.23M |
| Net Cash Per Share | -2.23 |
| Equity (Book Value) | 816.86M |
| Book Value Per Share | 6.82 |
| Working Capital | 21.38M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -24,349 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 26.10M |
| Net Borrowing | n/a |
| Free Cash Flow | -24,349 |
| FCF Per Share | -0.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | -31.66% |
| Operating Margin | -64.48% |
| Pretax Margin | -64.49% |
| Profit Margin | -60.04% |
| EBITDA Margin | 7.84% |
| EBIT Margin | -64.48% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -2.18% |
| FCF Yield | -0.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 26, 2018 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.06 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |